重症COVID-19急性低氧性呼吸衰竭ICU患者的高剂量地塞米松与氧疗策略:COVIDICUS随机临床试验
这项在法国19个ICU开展的多中心、安慰剂对照随机临床试验(2020年4月至2021年1月)纳入546例ICU成人COVID-19急性低氧性呼吸衰竭患者,采用2×3析因设计比较标准地塞米松与高剂量地塞米松,以及氧疗标准治疗、CPAP、HFNo2。高剂量地塞米松与标准地塞米松60天死亡率无差异(HR 0.96 [95%CI 0.69-1.33];P=.79);氧疗策略间28天IMV累积发生率无显著差异(o2SC vs CPAP:HR 1.08 [95%CI 0.71-1.63];o2SC vs HFNo2:HR 1.04 [95%CI 0.69-1.55]),60天死亡率亦无显著差异(o2SC vs CPAP:HR 0.97 [95%CI 0.58-1.61];o2SC vs HFNo2:HR 0.89 [95%CI 0.53-1.47])。干预间交互作用不显著。
要点
- 高剂量地塞米松(第1-5天20 mg/d,第6-10天10 mg/d)与标准地塞米松(6 mg/d×10天)60天死亡率无差异:HR 0.96(95%CI 0.69-1.33;P=.79)。
- 未初始接受IMV者中,o2SC vs CPAP的28天IMV累积发生率无显著差异:HR 1.08(95%CI 0.71-1.63)。
- o2SC vs HFNo2的28天IMV累积发生率无显著差异:HR 1.04(95%CI 0.69-1.55)。
- 60天死亡率在氧疗策略间无显著差异:o2SC vs CPAP HR 0.97(95%CI 0.58-1.61);o2SC vs HFNo2 HR 0.89(95%CI 0.53-1.47)。
- 干预间交互作用不显著。
适用人群与场景
- 法国19个ICU连续入组的成人COVID-19急性低氧性呼吸衰竭患者,共546例随机(中位[IQR]年龄67.4[59.3-73.1]岁;414例[75.8%]男性)。
- 不符合至少1种氧疗策略条件和/或已接受有创机械通气(IMV)者仅随机分配地塞米松干预。
- 未需IMV者额外随机分配至氧疗标准治疗(o2SC)、CPAP或HFNo2。
处置流程与药物剂量
- 标准地塞米松组:地塞米松磷酸盐6 mg/d,共10天(RECOVERY试验结果公布前入组者接受安慰剂)。
- 高剂量地塞米松组:地塞米松磷酸盐第1-5天20 mg/d,第6-10天10 mg/d。
- 未需IMV者随机接受氧疗标准治疗(o2SC)、CPAP或HFNo2。
研究设计与关键结果
- 研究类型:多中心、安慰剂对照随机临床试验,2×3析因设计,法国19个ICU,2020年4月至2021年1月,随访60天。
- 随机人数:筛查841例,随机546例;标准地塞米松276例(其中37例接受安慰剂),高剂量地塞米松270例。
- 氧疗随机:o2SC 109例(其中56例接受标准地塞米松)、CPAP 109例(其中57例接受标准地塞米松)、HFNo2 115例(其中56例接受标准地塞米松)。
- 主要终点(地塞米松):60天全因死亡率标准地塞米松 vs 高剂量地塞米松无差异,HR 0.96(95%CI 0.69-1.33;P=.79)。
- 主要终点(氧疗):28天IMV标准累积发生率o2SC vs CPAP无显著差异,HR 1.08(95%CI 0.71-1.63);o2SC vs HFNo2无显著差异,HR 1.04(95%CI 0.69-1.55)。
- 60天死亡率(氧疗):o2SC vs CPAP无显著差异,HR 0.97(95%CI 0.58-1.61);o2SC vs HFNo2无显著差异,HR 0.89(95%CI 0.53-1.47)。
- 干预间交互作用不显著。
证据类型、等级与局限
- 证据类型:多中心、安慰剂对照随机临床试验(RCT)。
对床旁实践的改变
- 在重症COVID-19急性低氧性呼吸衰竭ICU患者中,高剂量地塞米松未显著改善60天生存,不支持以高剂量地塞米松替代标准剂量地塞米松来改善生存。
- 未初始接受IMV者中,HFNo2或CPAP与氧疗标准治疗相比未显著改变28天IMV需求风险或60天死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The benefit of high-dose dexamethasone and oxygenation strategies vs standard of care for patients with severe acute hypoxemic respiratory failure (AHRF) caused by COVID-19 pneumonia is debated.
OBJECTIVES: To assess the benefit of high-dose dexamethasone compared with standard of care dexamethasone, and to assess the benefit of high-flow nasal oxygen (HFNo2) or continuous positive airway pressure (CPAP) compared with oxygen support standard of care (o2SC).
DESIGN, SETTING, AND PARTICIPANTS: This multicenter, placebo-controlled randomized clinical trial was conducted in 19 intensive care units (ICUs) in France from April 2020 to January 2021. Eligible patients were consecutive ICU-admitted adults with COVID-19 AHRF. Randomization used a 2 × 3 factorial design for dexamethasone and oxygenation strategies; patients not eligible for at least 1 oxygenation strategy and/or already receiving invasive mechanical ventilation (IMV) were only randomized for dexamethasone. All patients were followed-up for 60 days. Data were analyzed from May 26 to July 31, 2021.
INTERVENTIONS: Patients received standard dexamethasone (dexamethasone-phosphate 6 mg/d for 10 days [or placebo prior to RECOVERY trial results communication]) or high-dose dexamethasone (dexamethasone-phosphate 20 mg/d on days 1-5 then 10 mg/d on days 6-10). Those not requiring IMV were additionally randomized to o2SC, CPAP, or HFNo2.
MAIN OUTCOMES AND MEASURES: The main outcomes were time to all-cause mortality, assessed at day 60, for the dexamethasone interventions, and time to IMV requirement, assessed at day 28, for the oxygenation interventions. Differences between intervention groups were calculated using proportional Cox models and expressed as hazard ratios (HRs).
RESULTS: Among 841 screened patients, 546 patients (median [IQR] age, 67.4 [59.3-73.1] years; 414 [75.8%] men) were randomized between standard dexamethasone (276 patients, including 37 patients who received placebo) or high-dose dexamethasone (270 patients). Of these, 333 patients were randomized among o2SC (109 patients, including 56 receiving standard dexamethasone), CPAP (109 patients, including 57 receiving standard dexamethasone), and HFNo2 (115 patients, including 56 receiving standard dexamethasone). There was no difference in 60-day mortality between standard and high-dose dexamethasone groups (HR, 0.96 [95% CI, 0.69-1.33]; P = .79). There was no significant difference for the cumulative incidence of IMV criteria at day 28 among o2 support groups (o2SC vs CPAP: HR, 1.08 [95% CI, 0.71-1.63]; o2SC vs HFNo2: HR, 1.04 [95% CI, 0.69-1.55]) or 60-day mortality (o2SC vs CPAP: HR, 0.97 [95% CI, 0.58-1.61; o2SC vs HFNo2: HR, 0.89 [95% CI, 0.53-1.47]). Interactions between interventions were not significant.
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial among ICU patients with COVID-19-related AHRF, high-dose dexamethasone did not significantly improve 60-day survival. The oxygenation strategies in patients who were not initially receiving IMV did not significantly modify 28-day risk of IMV requirement.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04344730; EudraCT: 2020-001457-43.
参考来源
- Bouadma L, Mekontso-Dessap A, Burdet C, et al. High-Dose Dexamethasone and Oxygen Support Strategies in Intensive Care Unit Patients With Severe COVID-19 Acute Hypoxemic Respiratory Failure: The COVIDICUS Randomized Clinical Trial. JAMA Intern Med. 2022. PMID: 35788622. doi:10.1001/jamainternmed.2022.2168
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。